Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about experimenting with topical exosomes for hair loss treatment, alongside microneedling, Happy Head's gel-like topical, and Ordinary's hair serum. The user also mentions the availability of treatments like latanoprost and Redensyl.

The user is using finasteride 1.25mg three times a week for hair regrowth and reports no significant side effects except watery semen initially. They also use a local caffeine shampoo and are considering haircuts to improve appearance.

Baldness is difficult to cure because current treatments like finasteride, dutasteride, and minoxidil only prevent hair shedding, and new developments are mostly ineffective. Botox shows potential in aiding skin regeneration and hair growth, but maintenance therapy with treatments like dutasteride and minoxidil may still be necessary.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.

The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

The user reports using topical minoxidil 6% and finasteride 0.05% once daily, along with microneedling, vitamins, biotin, and nizoral shampoo. They recently increased minoxidil and finasteride to twice daily and feel their hair is thicker but are unsure about regrowth.

The conversation discusses hair regrowth using finasteride, minoxidil, and a dermaroller. Users also talk about the benefits of using a stamp over a derma roller for scalp treatment.

Switching from 2% liquid minoxidil to 5% foam minoxidil reduced scalp irritation but increased eyebrow flakiness and thinning. The user speculates that propylene glycol in the liquid formulation might have been protecting against seborrheic dermatitis while causing contact dermatitis.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.

Placebo hair regrowth might be influenced by propylene glycol in lotions or participants lying about using other treatments like minoxidil, finasteride, or microneedling. Being part of a study can also improve hair health due to lifestyle changes.

A user shared their 3.5-4 month progress using Topical Minoxidil, Oral Finasteride, Keto 1%, and Dermastamp, reporting positive results despite some shedding and flaking. Replies praised the progress and inquired about the treatment routine and temple condition.

The user is using Dutasteride, Minoxidil, microneedling, RU58841, and tretinoin for hair loss. They are experiencing shedding but notice new hair growth and are curious about the timing of future shedding phases.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

The user noticed hair thinning and has been using a treatment with minoxidil 2%, hydrocortisone butyrate, and 17 alpha estradiol for three months, seeing some regrowth. The user had dermatitis, now cured, which worsened the hair loss.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

The user completed a Clascoterone study with no observable changes in hair loss and plans to try microneedling and Minoxidil next. They will microneedle weekly and apply Minoxidil twice daily, except on the night of microneedling, and compare results after six months.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

Quercetin and houttuynia cordata extract may stimulate hair growth by enhancing cellular energy metabolism and increasing growth factor secretion. Quercetin has low oral bioavailability, and its natural tint might stain the scalp if used topically.

The user is seeking opinions on whether their hairline changes indicate regrowth or hair loss, using treatments like Rogaine, finasteride, microneedling, and Nizoral. They mention inconsistent finasteride use, scalp massages, and lifestyle factors like caffeine, nicotine, stress, and high sugar intake.

The user is using a routine involving microneedling, Minoxidil with tretinoin, a red light cap, scalp massages, Nizoral shampoo, and essence oil shampoo to address hair loss, with visible progress noted. They are considering topical finasteride or dutasteride if progress slows but are cautious due to past side effects.

The conversation discusses hair loss treatments, including microneedling, Nizoral, LLLT, Minoxidil, and Finasteride. The user experienced initial shedding reduction with Nizoral and LLLT, but shedding resumed with Minoxidil and Finasteride, which is considered a normal part of the treatment process.

The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.

The user shared their 12-month hair regrowth progress using 1mg finasteride, 5mg oral minoxidil, and topical minoxidil. They also used a derma stamp weekly and treated seborrheic dermatitis with Mometasone and Nizoral.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

The user experienced significant hair regrowth after using finasteride, minoxidil, and derma stamping, despite an initial heavy shedding phase. They also take omega-3, zinc, biotin, and folic acid daily, and report improved confidence and hair strength.

The user is concerned about patchy hair regrowth after 5.5 months of treatment. They are questioning if more hair growth can be expected in the upcoming months.